Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) kicked off on Monday, down -0.62% from the previous trading day, before settling in for the closing price of $1.60. Over the past 52 weeks, LXRX has traded in a range of $0.92-$3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 186.21% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 15.52%. With a float of $351.32 million, this company’s outstanding shares have now reached $361.49 million.
In an organization with 285 employees, it is important to assess its efficiency.
Lexicon Pharmaceuticals Inc (LXRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lexicon Pharmaceuticals Inc is 2.81%, while institutional ownership is 64.47%. The most recent insider transaction that took place on Nov 16 ’23, was worth 94,797. In this transaction Chief Executive Officer of this company bought 90,000 shares at a rate of $1.05, taking the stock ownership to the 914,359 shares. Before that another transaction happened on Nov 10 ’23, when Company’s Chief Executive Officer bought 10,000 for $1.01, making the entire transaction worth $10,100. This insider now owns 824,359 shares in total.
Lexicon Pharmaceuticals Inc (LXRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.52% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Take a look at Lexicon Pharmaceuticals Inc’s (LXRX) current performance indicators. Last quarter, stock had a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 157.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.66 million. That was inferior than the volume of 3.64 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.15%. Additionally, its Average True Range was 0.17.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 9.91%, which indicates a significant increase from 8.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.21% in the past 14 days, which was higher than the 82.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8571, while its 200-day Moving Average is $1.7853. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $1.6267. Second resistance stands at $1.6633. The third major resistance level sits at $1.6967. If the price goes on to break the first support level at $1.5567, it is likely to go to the next support level at $1.5233. Assuming the price breaks the second support level, the third support level stands at $1.4867.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
The company with the Market Capitalisation of 574.77 million has total of 246,237K Shares Outstanding. Its annual sales at the moment are 1,200 K in contrast with the sum of -177,120 K annual income. Company’s last quarter sales were recorded 1,650 K and last quarter income was -53,430 K.
